Last updated: March 8, 2024
Sponsor: Zeng Changhao
Overall Status: Active - Recruiting
Phase
N/A
Condition
Insomnia
Treatment
Stellate Ganglion Block
Lidocaine Hydrochloride
Clinical Study ID
NCT06255730
SGB shimian old
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Insomnia patients with the ages over 18.
- Meeting the diagnostic criteria for chronic insomnia as per the InternationalClassification of Sleep Disorders (ICSD) or the Diagnostic and Statistical Manual ofMental Disorders (DSM).
- Experiencing insomnia symptoms persistently for at least three months.
- Not currently using or ceased using medication for insomnia for at least four weeks.
- Willing to undergo Stellate Ganglion Block treatment and participate in the study.
Exclusion
Exclusion Criteria:
- Patients with severe cardiovascular disease, pulmonary disease, or other seriousphysical health issues.
- Pregnant or lactating women.
- Patients with mental disorders (such as major depression, anxiety disorders,schizophrenia, etc.) or cognitive impairments.
- Patients with known allergies or contraindications to Stellate Ganglion Blocktreatment.
- Patients currently participating in other clinical trials or receiving experimentaltreatments.
Study Design
Total Participants: 50
Treatment Group(s): 2
Primary Treatment: Stellate Ganglion Block
Phase:
Study Start date:
February 28, 2024
Estimated Completion Date:
June 30, 2024
Study Description
Connect with a study center
Peking University Sixth Hospital
Beijing, Beijing 450000
ChinaSite Not Available
Mianyang Central Hospital
Mianyang, Henan 450000
ChinaSite Not Available
Guanghan People's Hospital
Guanghan, Sichuan 618300
ChinaSite Not Available
Center Rehabilitation Hospital
Seoul,
Korea, Republic ofActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.